Josep V. Forment

AstraZeneca (United Kingdom) — United Kingdom

Medicine · Health Sciences

27h-index3.8kcitations104works8.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

PARP inhibition in cancer therapy(48), DNA Repair Mechanisms(46), CRISPR and Genetic Engineering(34), Cancer Genomics and Diagnostics(18), Genetic factors in colorectal cancer(15)

Publications104 total

Micronucleus quantification from whole-slide haematology images using AI serves as a translatable pharmacodynamic biomarker for DNA damage response inhibitors
Scientific Reports·2026Open Access
An Inducible BRCA1 Expression System with In Vivo Applicability Uncovers Activity of the Combination of ATR and PARP Inhibitors to Overcome Therapy Resistance
Cancers·2026Open Access
Genetic evidence for PARP1 trapping as a driver of PARP inhibitor efficacy in <i>BRCA</i> mutant cancer cells
Nucleic Acids Research·2025Open Access
Androgen receptor inhibition extends PARP inhibitor activity in prostate cancer models beyond BRCA mutations and defects in homologous recombination repair
NAR Cancer·2025· 1 citedOpen Access
An inducible BRCA1 expression system with <i>in vivo</i> applicability uncovers activity of the combination of ATR and PARP inhibitors to overcome therapy resistance
2025· 1 citedOpen Access
Abstract 4201: Combination of the PARP1-selective inhibitor saruparib with androgen receptor pathway inhibition provides combination benefit in preclinical models of prostate cancer with or without homologous recombination repair deficiency
Cancer Research·2025
High levels of DNA replication initiation factors indicate ATRi sensitivity via excessive origin firing
2025· 1 citedOpen Access
Site-selective photo-crosslinking for the characterisation of transient ubiquitin-like protein-protein interactions
PLoS ONE·2025· 2 citedOpen Access
Androgen receptor inhibition extends PARP inhibitor activity in prostate cancer models beyond BRCA mutations and defects in homologous recombination repair
2025
Understanding tumour growth variability in breast cancer xenograft models identifies PARP inhibition resistance biomarkers
npj Precision Oncology·2024· 2 citedOpen Access
Base editing screens define the genetic landscape of cancer drug resistance mechanisms
Nature Genetics·2024· 43 citedOpen Access
350 (PB338): Structural variants of BRCA1/2 represent a novel biomarker of homologous recombination deficiency in multiple tumour types
European Journal of Cancer·2024· 1 cited
The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models
Genome Medicine·2024· 51 citedOpen Access
Genome-scale clustered regularly interspaced short palindromic repeats screen identifies nucleotide metabolism as an actionable therapeutic vulnerability in diffuse large B-cell lymphoma
Haematologica·2024· 2 citedOpen Access
H2AX promotes replication fork degradation and chemosensitivity in BRCA-deficient tumours
Nature Communications·2024· 33 citedOpen Access
Abstract P22: C16orf72/HAPSTR1/TAPR1 Interacts with BRCA1 and Senataxin to Regulate R-loops at Stalled Replication Forks and Confer Resistance to PARP Disruption
Cancer Research·2024
Understanding tumour growth variability in patient-derived breast cancer xenograft models identifies early responders and biomarkers of resistance to PARP inhibition
2024Open Access
Author Correction: C16orf72/HAPSTR1/TAPR1 functions with BRCA1/Senataxin to modulate replication-associated R-loops and confer resistance to PARP disruption
Nature Communications·2023· 1 citedOpen Access
C16orf72/HAPSTR1/TAPR1 functions with BRCA1/Senataxin to modulate replication-associated R-loops and confer resistance to PARP disruption
Nature Communications·2023· 5 citedOpen Access
Simultaneous inhibition of DNA-PK and Polϴ improves integration efficiency and precision of genome editing
Nature Communications·2023· 108 citedOpen Access
page 1 of 6Next →

Frequent Co-authors

Stephen P. Jackson(18), Mark J. O’Connor(15), Julia Coates(7), Paul W.G. Wijnhoven(6), Yaron Galanty(6), David J. Adams(6), Violeta Serra(6), Mareike Herzog(5), Joshua Armenia(5), Elaine Cadogan(5), Alba Llop‐Guevara(5), Daniel Ramón(5), Beiyuan Fu(4), Fengtang Yang(4), Stephen T. Durant(4), Andrea Herencia-Ropero(4), Marta Guzmán(4), Olga Rodríguez(4), Carlos Caldas(4), Joaquı́n Arribas(4)